Acadia Healthcare enters today's Q1 earnings with one of the more charged short setups in healthcare — a position that has shifted materially over the past six weeks but still leaves the stock heavily contested.
Short interest tells the dominant story here. At roughly 25.6% of the free float, bears hold a meaningful stake. Yet the direction of travel is notable: SI peaked above 31% in mid-March, dropped sharply through April 9 as the stock recovered, then ticked back up 15% over the past week to sit near 25.5%. That bounce in short positioning, arriving just before the earnings release, points to fresh money re-entering rather than a clean unwind. The ORTEX short score of 63.6 — near the top decile for the sector — reinforces that this remains an actively contested name.
Borrow conditions, however, tell a more relaxed story. Cost to borrow is running at just 0.51%, low by any measure, and share availability has loosened substantially. The lending pool stood near its annual low in early April, consistent with peak short interest at the time. The subsequent relaxation in availability mirrors the partial short cover seen since mid-March. That combination — high but easing SI, cheap borrow, plentiful availability — suggests the bearish community is recalibrating rather than pressing hard into the print. Options lean slightly more cautious than usual: the put/call ratio is at 0.48, about 1.4 standard deviations above its 20-day average of 0.41, signalling a modest uptick in hedging demand. Still well short of the 52-week high of 1.57, this is not an alarm signal.
The analyst debate is pulling in different directions. The stock has rallied 23% over the past month to $28.26, yet the Street consensus price target sat at roughly $24 as of late April — meaning the stock has already run through where most analysts thought fair value was. TD Cowen raised its target to $30 and maintained Buy on April 28, and UBS lifted to $31 earlier in the month, both suggesting the bull thesis is live. Bears point to rising clinical costs and labor pressure squeezing margins, uncertainty around reimbursement policy, and lingering legal and government risk — a thesis that kept Barclays at Equal-Weight with a $20 target as recently as early March. At roughly 8x EV/EBITDA, valuation is not stretched by sector standards, but the stock's rapid re-rating from the low $20s has removed the obvious margin of safety that bulls cited earlier this year. Wellington Management added over 2.5 million shares as recently as February, while Greenlight Capital built a fresh position — both noteworthy given the concentrated institutional ownership profile.
The Q1 print will therefore test whether Acadia's operational recovery is real enough to justify a stock price that has already lapped the consensus target, or whether the short sellers who stayed in — and those who just returned — will find the margin story wanting.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
